CLINICAL_TRIALS trial_result · 2024-05-22

Clinical Trial Update: A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

Phase 2 trial of inhaled GB0139 in idiopathic pulmonary fibrosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Galecto Biotech AB | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Status: COMPLETED | Results posted: 2024-05-22